BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/31/2018 1:17:45 AM | Browse: 1055 | Download: 2318
 |
Received |
|
2017-11-13 08:59 |
 |
Peer-Review Started |
|
2017-11-13 10:33 |
 |
To Make the First Decision |
|
2017-11-30 05:53 |
 |
Return for Revision |
|
2017-12-03 06:27 |
 |
Revised |
|
2017-12-13 06:34 |
 |
Second Decision |
|
2017-12-19 10:46 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2017-12-20 02:14 |
 |
Articles in Press |
|
2017-12-20 02:14 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2017-12-25 08:22 |
 |
Typeset the Manuscript |
|
2018-01-26 05:55 |
 |
Publish the Manuscript Online |
|
2018-01-31 01:17 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Retrospective Study |
Article Title |
PIK3CA and TP53 mutations predict overall survival of stage Ⅱ/Ⅲ colorectal cancer patients
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Ajian Li, Huaguang Li, Erjiang Tang, Wei Wu, Ying Chen, Huihong Jiang, Moubin Lin and Lu Yin |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National Natural Science Foundation of China |
81272480 |
Science and Technology Commission of Shanghai Municipality |
15411969900 |
Science and Technology Commission of Shanghai Municipality |
16DZ2342200 |
|
Corresponding Author |
Lu Yin, PhD, Doctor, Doctor, Surgeon, Department of General Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, No.301 Yanchang Road, Shanghai 200072, China. yindalu@tongji.edu.cn |
Key Words |
Overall survival; Colorectal cancer; PIK3CA; TP53; 5-fluorouracil; Double mutation |
Core Tip |
Targeted next-generation sequencing was used to detect gene mutations rather than mutational hotspots in the present study. This manuscript is by far the first to report the predictive value of the combined mutation status of PIK3CA and TP53 in colorectal cancer patients receiving 5-FU-based adjuvant chemotherapy. Our data revealed that the double mutation of PIK3CA and TP53 is an independent predictive factor for overall survival in stage Ⅱ/Ⅲ patients receiving 5-FU-based chemotherapy. |
Publish Date |
2018-01-31 01:17 |
Citation |
Li AJ, Li HG, Tang EJ, Wu W, Chen Y, Jiang HH, Lin MB, Yin L. PIK3CA and TP53 mutations predict overall survival of stage Ⅱ/Ⅲ colorectal cancer patients. World J Gastroenterol 2018; 24(5): 631-640 |
URL |
http://www.wjgnet.com/1007-9327/full/v24/i5/631.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v24.i5.631 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345